After more than a decade of collaboration among advocates, patients, industry, and medical professionals, the U.S. Food and Drug Administration (FDA) has granted approval to SpringWorks Therapeutics for its gamma secretase inhibitor, OGSIVEO™ (nirogacestat), for the treatment of adults with progressing desmoid tumors.
This drug is the first-ever FDA-approved medical therapy for desmoid tumors and represents a beacon of hope for desmoid tumor patients.
